Nav: Home

Linagliptin improved albuminuria but effect on eGFR and CV risk in patients with diabetes

June 14, 2019

Diabetes mellitus is a significant and growing health problem which contributes significantly to the prevalence of chronic kidney disease (CKD). According to the ERA-EDTA Registry, nearly a quarter (23%) of all patients who started renal replacement therapy in 2016 were patients with diabetes. The underlying idea of the study, which has been presented as a late breaking clinical trial at the ERA-EDTA congress in Budapest today, was to assess the potential of the DPP-4 inhibitor linagliptin (LINA), an oral diabetes drug, to reduce the burden of CKD and cardiac complications as secondary diseases in people with diabetes. Only a few weeks ago it had been shown that SGLT2 inhibitors, another class of diabetes drugs, could slow CKD progression in this patient group.

Dipeptidyl peptidase-4 (DPP-4) inhibitors are usually prescribed for patients with type 2 diabetes as second or third line drugs, when there is not sufficient treatment response to more widely used drugs like metformin. DPP-4 inhibitors block the enzyme DPP-4, which destroys incretins. Incretins stimulate the production of insulin and, thus, the blood sugar level decreases with the medication.

"But do DPP-4 inhibitors have any beneficial renal and cardiovascular effects? Can they prevent these secondary diseases of diabetes? This is what we wanted to find out in our trial," explains lead investigator Professor Dr Christoph Wanner. The multicenter, randomized, double-blind CARMELINA trial compared LINA 5 mg vs placebo, added to standard of care, in people with type 2 diabetes and CV and/or kidney disease. The study assessed the cardio-renal disease burden and effects of the medication on CV, eGFR and albuminuria outcomes in participants with or without nephrotic-range proteinuria (defined as UACR ?2200 mg/g at baseline).

It showed that 646 of the 6979 randomized participants had nephrotic-range proteinuria and, thus, suffered from renal disease. They were at high risk of CV events and had poor kidney outcomes; a 3-fold greater decline in eGFR was seen in those with nephrotic-range proteinuria at baseline

The difference in HbA1c over the full trial duration favoured LINA (-0.36%). This did not differ between patients who had nephrotic-range proteinuria at baseline and those who had not. A larger proportion of patients who had received LINA vs placebo regressed to normoalbuminuria or had a reduction of urine albumin-to-creatinine ratio of ?50% from baseline - regardless of nephrotic-range proteinuria status. However, loss in eGFR over time was not different between the groups (-6.51/year vs placebo -7.07/year), and the medication did not affect the risk for so called 3-point major adverse cardiovascular events (HR.1.02 [95% CI, 0.89, 1.17]), CV mortality (0.96 [0.81, 1.14]), or all-cause hospitalization (0.93 [0.85, 1.00]), in people with or without nephrotic-range proteinuria

"Linagliptin is effective in lowering HbA1c and albuminuria, but this did not translate into a better renal and cardiac outcome. It controlled the diabetes and it could halt albuminuria, but it had no additional clinical benefits. But the study clearly showed that there is a group of patients with diabetes who clearly are in need of outcome-enhancing therapies, because their prognosis is rather poor. Nephrotic-range proteinuria might be a good marker to stratify these patients. I would advise to treat these patients with SGLT2 inhibitors instead, or a combination of SGLT2 inhibitor and DPP-4 inhibitor. Apart from diabetes control, SGLT2 inhibitors have shown to be effective in renal and cardiovascular risk reduction [2]", concluded lead investigator Professor Wanner.
-end-
[1] Wanner C et al. Effects on kidney outcomes in patients with nephrotic range proteinuria: Insights from CARMELINA. LBCT Abstract ERA-EDTA Congress 2019, Budapest

[2] Perkovic V et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal 2019; 15 Apr. [epub ahead of print]; DOI: 10.1056/NEJMoa1811744

About ERA-EDTA

With more than 7,000 active members, the ERA-EDTA is one of the biggest nephrology associations worldwide leading European nephrology and one of the most important European Medical Associations. It organises annual congresses and a Scientific Education Interactive Day (SEID), it produces guidelines, it collects data and performs epidemiological studies through its Registry. It supports fellowships and research projects. Its publications are NDT and CKJ (this last journal is Open Access). The ERA-EDTA also has an online Educational platform: the European Nephrology Portal (ENP) which includes NDT-Educational@ENP. The 2020 Congress will be held June 6-9 in Milan (Italy). Visit the booth to receive more information! Web site: http://www.era-edta.org

ERA-EDTA

Related Diabetes Articles:

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
The Lancet Diabetes & Endocrinology: Older Americans with diabetes living longer without disability, US study shows
Older Americans with diabetes born in the 1940s are living longer and with less disability performing day to day tasks than those born 10 years earlier, according to new research published in The Lancet Diabetes & Endocrinology journal.
Reverse your diabetes -- and you can stay diabetes-free long-term
A new study from Newcastle University, UK, has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.
More Diabetes News and Diabetes Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#544 Prosperity Without Growth
The societies we live in are organised around growth, objects, and driving forward a constantly expanding economy as benchmarks of success and prosperity. But this growing consumption at all costs is at odds with our understanding of what our planet can support. How do we lower the environmental impact of economic activity? How do we redefine success and prosperity separate from GDP, which politicians and governments have focused on for decades? We speak with ecological economist Tim Jackson, Professor of Sustainable Development at the University of Surrey, Director of the Centre for the Understanding of Sustainable Propserity, and author of...
Now Playing: Radiolab

An Announcement from Radiolab